Article

Pseudoprogression in Immunotherapy and Identification of Clinical-Biologic Predictive Factors: A Retrospective Pan-Tumor Cohort Study

2025-10-17

Abstract excerpt

<title>Abstract</title> <p>Background Immune Checkpoint inhibitors (ICI) have emerged as one of the leading cancer therapies. Inflammatory mechanism induced by ICI can lead to increased tumor lesions that could be wrongly misinterpreted as progressive disease (PD). Currently, there are no imaging modalities that can differentiate true progression from pseudoprogression (PP). Although the iRECIST criteria have bee...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 79abe332-5dad-537d-b639-f721f5b2f3ac
DOI: 10.21203/rs.3.rs-7765256/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pseudoprogression in Immunotherapy and Identification of Clinical-Biologic Predictive Factors: A Retrospective Pan-Tumor Cohort StudyDOI 10.21203/rs.3.rs-7765256/v1Read

Hyperprogressive disease in patients receiving immune checkpoint inhibitors.Semantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read

First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature ReviewSemantic proximity Read

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).Semantic proximity Read

Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.Semantic proximity Read

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinomaSemantic proximity Read

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC.Semantic proximity Read

Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)Semantic proximity Read

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics.Semantic proximity Read

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity Read

BATPC: A biology-anchored tumor progression classification for interpreting multidimensional progression phenotypes across solid tumors.Semantic proximity Read